All In Biotech

Drug Trial Radar · NCT04566380

ONO-4538 Phase II Rollover Study (ONO-4538-98)

A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination With Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Sep 10, 2020

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.

Conditions

  • Pan-tumor

Interventions

  • ONO-4538Drug

    IV infusion over 30 minutes

  • oxaliplatinDrug

    IV infusion over 2 hours

  • S-1Drug

    Administered orally twice daily

  • capecitabineDrug

    Administered orally twice daily

  • bevacizumabDrug

    IV infusion over 30 minutes

  • temozolomideDrug

    Administered orally once daily for 5 days every 28 days

  • IpilimumabDrug

    IV infusion over 30 minutes

  • ONO-7703Drug

    Administered orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (Aes)Time frame: From Day 1 up to 28 days after the end of the treatment phase

Locations

44 sites in 3 countries. Site status is shown where the registry gives one.

  • Chiba Clinical Site2

    Chiba, Chiba, Japan · Completed

  • Chiba Clinical Site1

    Kashiwa, Chiba, Japan · Completed

  • Ehime Clinical Site1

    Matsuyama, Ehime, Japan · Completed

  • Fukuoka Clinical Site2

    Fukuoka, Fukuoka, Japan · Completed

  • Fukuoka Clinical Site3

    Fukuoka, Fukuoka, Japan · Completed

  • Fukuoka Clinical Site1

    Kurume, Fukuoka, Japan · Completed

  • Hiroshima Clinical Site1

    Hiroshima, Hiroshima, Japan · Recruiting

  • Hokkaido Clinical Site1

    Sapporo, Hokkaido, Japan · Recruiting

  • Hyogo Clinical Site1

    Akashi, Hyōgo, Japan · Completed

  • Kanagawa Clinical Site1

    Yokohama, Kanagawa, Japan · Completed

  • Kyoto Clinical Site1

    Kyoto, Kyoto, Japan · Recruiting

  • Oita Clinical Site1

    Yufu, Oita Prefecture, Japan · Recruiting

  • Okayama Clinical Site1

    Okayama, Okayama-ken, Japan · Recruiting

  • Osaka Clinical Site2

    Osaka, Osaka, Japan · Recruiting

  • Osaka Clinical Site1

    Suita, Osaka, Japan · Recruiting

  • Osaka Clinical Site3

    Takatsuki, Osaka, Japan · Recruiting

  • Saitama Clinical Site1

    Hidaka, Saitama, Japan · Recruiting

  • Saitama Clinical Site2

    Kitaadachi-gun, Saitama, Japan · Completed

  • Tokyo Clinical Site3

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • Tokyo Clinical Site2

    Chuo-ku, Tokyo, Japan · Recruiting

  • Tokyo Clinical Site1

    Koto-ku, Tokyo, Japan · Completed

  • Tokyo Clinical Site5

    Koto-Ku, Tokyo, Japan · Recruiting

  • Tokyo Clinical Site4

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Daegu Clinical Site2

    Daegu, South Korea · Recruiting

  • Daegu Clinical Site3

    Daegu, South Korea · Recruiting

  • Gyeonggi-do Clinical site1

    Gyeonggi-do, South Korea · Recruiting

  • Hwasun Clinical Site1

    Hwasun, South Korea · Recruiting

  • Incheon Clinical Site1

    Incheon, South Korea · Completed

  • Seoul Clinical Site1

    Seoul, South Korea · Recruiting

  • Seoul Clinical Site2

    Seoul, South Korea · Completed

  • Seoul Clinical Site3

    Seoul, South Korea · Recruiting

  • Seoul Clinical Site4

    Seoul, South Korea · Recruiting

  • Seoul Clinical Site5

    Seoul, South Korea · Recruiting

  • Seoul Clinical Site6

    Seoul, South Korea · Recruiting

  • Suwon Clinical Site1

    Suwon, South Korea · Recruiting

  • Daegu Clinical Site1

    Daegu, South Korea, South Korea · Recruiting

  • Kaohsiung Clinical Site1

    Kaohsiung City, Taiwan · Completed

  • Kaohsiung Clinical Site2

    Kaohsiung City, Taiwan · Completed

  • New Taipei City Clinical Site1

    New Taipei City, Taiwan · Recruiting

  • Tainan Clinical Site1

    Tainan, Taiwan · Recruiting

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.